Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9060400 | 0.84 | PDK1 (0.41) | SLC6A9PDK1GLRA1 | |
| SCHEMBL27991068 | 0.83 | PDK1 (0.40) | SLC6A9PDK1GLRA1 | |
| SCHEMBL12332159 | 0.81 | SLC6A9 (0.39) | SLC6A9PDK1HRH3ALDH1A1 | |
| SCHEMBL12233419 | 0.81 | SLC6A9 (0.39) | SLC6A9PDK1HRH3ALDH1A1 | |
| SCHEMBL12206881 | 0.81 | SLC6A9 (0.39) | SLC6A9PDK1HRH3ALDH1A1 | |
| SCHEMBL12110186 | 0.81 | HRH3 (0.41) | PDK1GLRA1HRH3 | |
| SCHEMBL2306205 | 0.81 | HRH3 (0.41) | PDK1GLRA1HRH3 | |
| SCHEMBL12110189 | 0.81 | HRH3 (0.41) | PDK1GLRA1HRH3 | |
| SCHEMBL9449721 | 0.79 | ALDH1A1 (0.44) | PDK1GLRA1HRH3ALDH1A1 | |
| SCHEMBL457462 | 0.77 | ALDH1A1 (0.42) | SLC6A9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501438-B2 | Pyridoimidazole derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | US | disclosed |
| WO-2008005908-A2 | PYRIDOIMIDAZOLE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | disclosed |
| US-20050282387-A1 | Metal polish composition, polishing method using the composition and method for producing wafer using the polishing method | SHOWA DENKO K.K. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1517972-A1 | METAL POLISH COMPOSITION, POLISHING METHOD USING THE COMPOSITION AND METHOD FOR PRODUCING WAFER USING THE POLISHING METHOD | Showa Denko K.K. (JP) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003104350-A1 | METAL POLISH COMPOSITION, POLISHING METHOD USING THE COMPOSITION AND METHOD FOR PRODUCING WAFER USING THE POLISHING METHOD | SHOWA DENKO K.K. (JP) | 2003-12-18 | — | — | WO | disclosed |
| US-6294573-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPENIAS SUCH AS OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, AND TUMOR GROWTH AND METASTASIS OR INVASION | ABBOTT LABORATORIES | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009491-A1 | 1-(3-naphthalen-1-yl-imidazo[1,5-a]pyridin-1-yl)-butan-1-one; chronic pain, an inflammatory disorder, rheumatoid arthritis, multiple sclerosis, osteoporosis and osteoarthritis; cannabinoid receptor ligands | CNR1, CNR2, OPRK1 | SLC6A9 4813/4885PDK1 3780/4885GLRA1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.